Previous 10 | Next 10 |
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion o...
Immune Therapeutics (IMUN) received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing debt.Under the agreement, the investors will lend a minimum of $700K and a maximum of $1.5M to the...
Orlando, Florida, June 02, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUND) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion o...
Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. The reverse stock split was completed with the state of Florida on March...
WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect. Both events will be held virtually ...
For Immune Therapeutics ([[IMUN]] +362.0%) the combination of Cytocom and Cleveland BioLabs business means that shareholders who hold a considerable stake in Cytocomcan can realize value.The Cytocom platform technologies and product pipeline, in combination with Cleve...
WINTER PARK, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced...
Cytocom has agreed to reacquire the emerging market rights for its late-stage drug candidates CYTO-201 and CYTO-401, from Immune Therapeutics ( OTCPK:IMUN ) in exchange of up to ~$5M of Immune liabilities. More news on: Immune Therapeutics, Inc., Healthcare stocks news, ...
WINTER PARK, Fla. , Aug. 20, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a clinical-stage biopharmaceutical company developing novel immune modulating therapies based on proprietary platforms, today announced the company and Immune Therapeutics, Inc. (OTC: IMUN; Immune) have entered i...
Orlando, Florida, July 07, 2020 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” “IMUN” or the “Company”), a biopharmaceutical company focused on the development of therapies for the treatment of Infectious diseases con...
News, Short Squeeze, Breakout and More Instantly...
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of H. Louis Salomonksy, a dedicated member of its Board of Directors. Mr. Salomonksy pas...
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp . (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc . The joint resear...
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-12...